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Abstract
Background
External quality assurance (EQA) systems are essential to ensure accurate diagnosis of TB
and drug-resistant TB. The implementation of EQA through organising regular EQA rounds
and identification of training needs is one of the key activities of the European TB reference
laboratory network (ERLTB-Net). The aim of this study was to analyse the results of the
EQA rounds in a systematic manner and to identify potential benefits as well as common
problems encountered by the participants.
Methods
The ERLTB-Net developed seven EQAmodules to test laboratories’ proficiency for TB
detection and drug susceptibility testing using both conventional and rapid molecular tools.
All National TB Reference laboratories in the European Union and European Economic
Area (EU/EEA) Member States were invited to participate in the EQA scheme.
Results
A total of 32 National TB Reference laboratories participated in six EQA rounds conducted
in 2010–2014. The participation rate ranged from 52.9% - 94.1% over different modules and
rounds. Overall, laboratories demonstrated very good proficiency proving their ability to
diagnose TB and drug-resistant TB with high accuracy in a timely manner. A small number
of laboratories encountered problems with identification of specific Non-tuberculous Myco-
bacteria (NTMs) (N = 5) and drug susceptibility testing to Pyrazinamide, Amikacin, Capreo-
mycin, and Ethambutol (N = 4).
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Conclusions
The European TB Reference laboratories showed a steady and high level of performance in
the six EQA rounds. A network such as ERLTB-Net can be instrumental in developing and
implementing EQA and in establishing collaboration between laboratories to improve the
diagnosis of TB in the EU/EEA.
Introduction
Tuberculosis (TB) remains an important public health problem globally and within the Euro-
pean Union (EU) despite significant progress made in the past decade. In 2013, 64 844 TB
cases were reported in 28 EU and two European Economic Area (EEA) countries, 6% less than
in 2012 and reflecting a decrease in 19 countries [1]. TB notification rates remained high
(>40.0/100,000) in three countries (Latvia, Lithuania, and Romania) with the highest incidence
estimated in Romania (87.0/100,000) (1). Although there has been a steady decrease in TB
notification rates both in EU/EEA countries and the World Health Organisation (WHO) Euro-
pean Region as a whole over the last decade (1), the target of 50% reduction of TB prevalence
by 2015 set up by The Stop TB Partnership, which is linked to the Millennium Development
Goals, is unlikely to be achieved. Despite the low percentage of multidrug-resistant (MDR) TB
in the EU/EEA region (4.1%), the proportion of MDR TB remained high in Latvia, Lithuania,
and Estonia (11.6, 18.9, and 22.7%, respectively) [1].
Timely and accurate diagnosis of active TB is a prerequisite for any successful TB control
programme and an essential part of the action framework to eliminate TB in low-incidence
countries [2]. The laboratory plays a key role in TB diagnosis both at individual and program-
matic level through detection of active TB cases and drug susceptibility testing (DST), contrib-
uting to contact tracing and surveillance through highly discriminatory genotyping as well as
latent TB infection diagnosis [3–7]. In addition, detection of drug resistance is crucial for
administering optimal treatment regimens and prevention of transmission.
To ensure compliance with existing international standards of laboratory diagnostics [8], all
laboratories in the EU should be accredited by the relevant national bodies. Adequate labora-
tory infrastructure and facilities as well as appropriately trained and qualified personnel and
both Internal and External Quality Assurance (IQA and EQA) systems are essential for obtain-
ing and retaining accreditation [9]. Participation of TB diagnostic laboratories in various EQA
schemes organised by international bodies and recognised providers has proven effective in
maintaining and improving laboratory proficiency across the EU/EEA and elsewhere [10–12].
The introduction of new drug susceptibility testing methods, including rapid culture and
molecular tools, and genotyping methodologies necessitated the development of novel as well as
modification of existing EQA schemes (eg for rapid molecular tools). A series of recent reports
revealed specific problems related to a lack of standardisation in second-line drug (SLD) suscep-
tibility testing and multilocus MIRU-VNTR genotyping [13–15]. The development and imple-
mentation of advanced EQA schemes can identify these problems early and address them
through networking activities and collaboration at national and supranational level.
A situation analysis of national TB reference functions across the EU [3] formed the basis for
launching the European Reference Laboratory Network for TB (ERLTB-Net, formerly
ERLN-TB) in January 2010. The network was established to meet the objectives and strategies
described in the `Framework Action Plan to Fight Tuberculosis’ [16]. The network is co-ordi-
nated by the European Centre for Disease Prevention and Control (ECDC) and a consortium of
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partners led by Public Health England (PHE). It aims to consolidate and strengthen TB labora-
tory capacity, improve quality and achieve sustainability in TB laboratory diagnosis through pro-
vision of training, harmonisation of laboratory methods, development and implementation of
reliable EQA systems and standards in TB laboratory diagnosis within the EU/EEA and beyond
as well as supporting the functionality of national TB laboratory networks. The development of a
sustainable EQA system constitutes one of the major network activities. The developed system
has been implemented through regular EQA rounds and in-depth analysis of the results, address-
ing identified challenges through training, task-force visits and other mechanisms. Initial insights
into the results of proficiency testing for DST were published in 2013 [15].
The aim of this study was to systematically analyse the implementation of the EQA scheme
across the network from 2010 to 2014, assess performance of the laboratories, identify common
problems and discuss the potential benefits of the scheme for the participants.
Materials and Methods
Participating laboratories and study design
A total of six EQA rounds were conducted from 2010 to 2014 (Table 1). All 34 National TB Ref-
erence laboratories (NRL) nominated by relevant national bodies were invited to participate in
the EQA. Panels of specimens (except crude DNA extracts for Module 7) were prepared at the
NRL Germany, shipped to INSTAND e.V. (an independent non-profit interdisciplinary scien-
tific medical society, nominated as a Collaborating Centre for Quality Assurance and Standardi-
sation in Laboratory Medicine of theWorld Health Organisation since 1994) and distributed
across the ERLTB-Net network. Crude DNA extracts were prepared at the PHE National Myco-
bacterium Reference Laboratory (NMRL) and distributed via INSTAND e.V. The test results of
the EQA samples were sent back to INSTAND e.V. by the participating laboratories. Scoring
and analysis was done jointly by INSTAND e.V. and NRL Germany and individual results were
reported back to the participants. Participation in EQA rounds was voluntary and free of charge
for all participating laboratories. All laboratories ensured safe working conditions and partici-
pated only in the modules covering procedures performed routinely in their laboratories.
Table 1. External Quality Control modules and specimen panel composition for six rounds, 2010–2014.
EQA modules Round 1 Spring
2010
Round 2 Autumn
2010
Round 3 2011 Round 4 2012 Round 5 2013 Round 6 2014
1 Microscopy 6 slides 6 slides 6 slides 6 slides 6 slides 6 slides
2 Primary Isolation 5 spiked sputum
specimens
5 spiked sputum
specimens
5 spiked sputum
specimens
5 spiked sputum
specimens
5 spiked sputum
specimens
5 spiked sputum
specimens
3 Identiﬁcation 5 M. spp strains 5 M. spp strains 5 M. spp strains 5 M. spp strains 5 M. spp strains 5 M. spp strains
4 Drug susceptibility
testing
5 M. tuberculosis
strains
5 M. tuberculosis
strains
10 M.
tuberculosis
strains
10 M.
tuberculosis
strains
5 M. tuberculosis
strains
5 M. tuberculosis
strains
5 Rapid NAAT
identiﬁcation of
Mycobacteria
Not performed Not performed 5 spiked sputum
specimens
5 spiked sputum
specimens
5 spiked sputum
specimens
4 spiked sputum
specimens
6 Molecular DST
(cultures)
Not performed 5 M. tuberculosis
strains
10 M.
tuberculosis
strains
10 M.
tuberculosis
strains
10 M.
tuberculosis
strains
5 M. tuberculosis
strains
7 Molecular DST (crude
extracts)
Not performed Not performed 6 crude DNA
extracts
6 crude DNA
extracts
Not performed Not performed
EQA, External Quality Control. NAAT, Nucleic Acid Ampliﬁcation Tests. DST, Drug Susceptibility Tests. M. spp, various Mycobacterium genus species
doi:10.1371/journal.pone.0152926.t001
External Quality Assessment for TB Laboratory Diagnosis
PLOS ONE | DOI:10.1371/journal.pone.0152926 April 7, 2016 3 / 14
EQAmodules
The ERLTB-Net developed seven modules covering various types of laboratory techniques: (1)
microscopy; (2) primary isolation; (3) identification; (4) drug susceptibility testing; (5) nucleic
acid amplification testing (NAAT) for rapid detection of Mycobacteria; (6) molecular drug sus-
ceptibility testing using cultures; and (7) molecular drug susceptibility testing using crude
DNA extracts (Table 1).
Artificial sputa (spiked with mycobacteria) were used for preparation of slides (for micros-
copy) and specimens for primary isolation and rapid NAAT-based detection; all specimens in
the latter panels contained equal concentrations of Mycobacteria. For identification and DST,
strains with validated characteristics (Mycobacterium species and drug susceptibility profiles)
were used. Specimen panels included strains with varying DST profiles (S1 Table); no MDR
strains were included due to safety concerns. Crude DNA extracts for Module 7 were prepared
using heat-lysedM. tuberculosis suspensions treated with chloroform [17]; among these non-
hazardous samples, DNA isolated fromMDR strains was included (S2 Table). Module 3 panels
comprised ofM. tuberculosis complex (MTBC) strains (M. tuberculosis,M. bovis BCG.M. bovis
subsp caprae,M. bovis subsp bovis) as well as non-tuberculous mycobacteria (NTM) (M. gordo-
nae,M. kansasii,M. fortuitum,M. abscessus,M. szulgai,M. intracellulare,M. celatum,M. chelo-
nae,M. avium,M.marinum,M. simiae, and M.malmoense) in various combinations.
Methods used in participating laboratories
The laboratories used their routine methods to test the specimens provided within the EQA
panels. The laboratories were asked to report on the methods used for smear microscopy, rapid
detection of Mycobacteria (Modules 1 and 5) and (optionally) methods used for species identi-
fication (Module 3).
Data analysis and laboratory certification
Reports received from participating laboratories were analysed against reference results as deter-
mined by the EQA provider (NRL Germany and INSTAND e.V), and the percentage of correct
results in each module was calculated by dividing the number of correct results by the total
number of tests in the module. This provided the score for the given laboratory in the given
module. If not all tests within a given module were performed (for example, for second line
DST), the overall score was adjusted accordingly. Laboratories scoring80% were issued per-
formance certificates for individual modules. Their individual performances were referred to as
“good” (scores 80.0. . .99.9%) and “excellent’(100.0%) and overall performance of laboratories
achieving 80% score was collectively termed “good”. Scores under 80% were considered to indi-
cate poor performance for the specific module(s) and no EQA certificate was issued [15].
Error rates for specific methods were calculated as a proportion of incorrect results relative
to a total number of individual tests performed by all laboratories across all rounds; for exam-
ple in Modules 5 and 6 data was analysed by individual drugs. Proportions were compared
using the chi-square test using GraphPad Prizm (La Jolla, California, USA). A p-value< 0.05
was considered as significant.
Results
The number of participating laboratories varied across EQA rounds and modules with the larg-
est number of laboratories (N = 32) participating in theMycobacterium species identification
module in round 1 comprising 94.1% of laboratories within the network (Fig 1). These 32
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laboratories represented 27 EU/EEA Member States (five countries have more than one labora-
tory with NRL status).
Performance characteristics of participating laboratories in the EQA rounds 1–6 are sum-
marised in Fig 2.
Module 1 –Microscopy
The proportion of laboratories using Ziehl-Neelsen (ZN) staining for smear microscopy (Mod-
ule 1) varied from 46.0% to 58.0% with the remaining laboratories using primarily auramine
fluorescent staining; a small number of laboratories (varying from 1 to 4 in different rounds)
used the Kinyoun method.
There were minor variations in the numbers of laboratories participating in the proficiency
testing for microscopy in different rounds with the largest number (N = 27) taking part in
round 5 and the smallest (N = 23) in rounds 2 and 4. In rounds 2–6, laboratories demonstrated
good and excellent performance with only a small number (one in round 2, two in round 3,
zero in round 4 and 5, and one in round 6) of laboratories failing to achieve the 80% threshold.
The proportion of laboratories that were awarded certificates was 80.8% in round 1 and 96.2%
in round 6. There were no significant differences in error rates and overall performance charac-
teristics between laboratories using different smear staining methods (ZN, auramine, or
Kinyoun) (Fig 3).
Module 2 – Primary isolation
Within module 2, laboratories were requested to detect the presence of mycobacteria in artifi-
cial spiked sputum specimens using bacteriological culture, and (if routinely performed) differ-
entiateM. tuberculosis complex from NTM and identifyMycobacteria species using a range of
phenotypic and/or molecular tools. The number of participating laboratories varied from 23
(round 3) to 29 (round 1). Overall scores were good and excellent with only one laboratory in
rounds 4 and 6 failing to achieve the 80% threshold. The proportion of laboratories reporting
Fig 1. Laboratories participating in EQA rounds andmodules.
doi:10.1371/journal.pone.0152926.g001
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results of species identification varied from 64.3% to 95.7% in different years and largely
depended on the composition of the EQA panels (MTBC or NTM) as not all laboratories iden-
tify the same spectrum of NTM species routinely on primary specimens. Common problems
encountered by the laboratories included reporting the presence of mycobacteria in negative
specimens (probably indicating cross-contamination, N = 5), and inability to detect NTM in
positive specimens (N = 2).
Fig 2. Results of proficiency testing in rounds 1 to 6 by module.
doi:10.1371/journal.pone.0152926.g002
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Module 3 – Species identification
In module 3, participants performed species identification of mycobacterial cultures using phe-
notypic or molecular tools or a combination of both based on standard protocols adopted in
those laboratories. The number of participating laboratories ranged from 21 (Rounds 2 and 5)
to 32 (Round 1).
Within this module, performance varied considerably with a total of three laboratories
across all rounds achieving low scores of 20–40% (in rounds 1, 2, and 4) and one laboratory
misidentifying all specimens in round 5. The majority of participating laboratories, however,
demonstrated either good or excellent performance. The proportion of laboratories that were
awarded certificates varied from 85.2% (round 4) to 100% (round 6). Common problems expe-
rienced by the laboratories included misidentification of NTM and misidentification of species
within theM. tuberculosis complex (a total of 24 incorrect NTM identifications and 16 incor-
rect identifications within theM. tuberculosis complex in all rounds) withM. bovis caprae and
M. bovis BCG being the most problematic species.
Module 4 – Phenotypic drug susceptibility testing
In module 4, laboratories were requested to test five (modules 1–2 and 5–6) or ten (modules 3
and 4)M. tuberculosis cultures for sensitivity to five first-line drugs (FLD) (all modules) and
additionally to fluoroquinolones (FQ), capreomycin (CAP), amikacin (AMK), and kanamycin
(KAN) (Modules 3–5) or FQ, CAP, and AMK (Modules 2 and 6) using any validated pheno-
typic method routinely used in the laboratory. All but one laboratory used automated liquid
culture-based systems (Bactec MGIT960, Becton Dickinson, New Jersey, USA) for DST for sec-
ond line drugs; for FLD including PZA methods varied and included Bactec MGIT960 as well
as the proportion method on solid media and resistance ratio method on semi-solid and liquid
media for PZA.
The number of laboratories taking part in module 4 varied from 22 (Rounds 5 and 6) to 31
(Round 1) and overall performance was good with only two laboratories failing to achieve 80%
in one round (round 2). Only susceptibility to rifampicin (RIF) and isoniazid (INH) was tested
by all participating laboratories; other drugs were tested by a smaller number of laboratories in
Fig 3. Smearmicroscopy error rates for microscopy diagnosis by Ziehl-Neelsen, auramine or
Kinyounmethods.
doi:10.1371/journal.pone.0152926.g003
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accordance with their routine practices. Importantly, the proportion of laboratories routinely
testing for susceptibility to pyrazinamide (PZA), FQ and AMK increased over the five years
from 65.0%, 56.6%, and 52.2% to 100.0%, 77.3%, and 77.3%, respectively, confirming the ability
of many laboratories to detect extensively drug-resistant (XDR) strains.
Error rates varied substantially between drugs (Fig 4). PZA was consistently the most prob-
lematic drug (41 incorrect results comprising 5.0% of all drug susceptibility tests) followed by
AMK, ethambutol (EMB) and streptomycin (STR) (13, 20 and 11 errors comprising 2.2%,
2.1%, and 1.9%, respectively). The proportion of incorrect results for other second-line drugs
(FQ and KAN) was lower and similar to that for INH and RIF.
Module 5 – Rapid identification of mycobacteria using molecular tools
This module was designed to test proficiency of laboratories in rapidly detecting MTB complex
bacteria in sputum specimens using nucleic acid amplification tests (NAAT). The number of
participating laboratories ranged from 19 (Round 4) to 22 (remaining rounds) and perfor-
mance was good with all but two laboratories (in Rounds 5 and 6) achieving scores>80%. The
proportion of laboratories using GeneXpert (Cepheid, Sunnyvale, USA) methodology for TB
detection in primary specimens increased from 35.0% in 2011 to 65.2% in 2014. Other methods
used for TB detection in primary specimens included BD ProbeTec DTB (Becton Dickinson,
New Jersey, USA) used by up to 13.6% of laboratories in different years, and Cobas TaqMan
(Roche, Pleasanton, USA) GT Mycobacteria Direct (Hain Lifescience GmbH, Nehren,
Fig 4. Error rates for tuberculosis drug susceptibility testing by phenotypic tools andmolecular tools grouped by individual drugs. INH, isoniazid;
RIF, Rifampicin; EMB, Ethambutol; PZA, pyrazinamide; STR, streptomycin; FQ, fluoroquinolones; AMK, amikacin; CAP, capreomycin; KAN, Kanamycin;
AG/CP, aminoglycosides/cyclic peptides. DST, Drug Susceptibility Testing. For molecular tests, a combined resistance to injectable drugs (“AG/CP”) was
reported instead of individual resistance to AMK, CAP, and KAN.
doi:10.1371/journal.pone.0152926.g004
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Germany), and Artus PCR kit (QIAGEN GmbH, Hilden, Germany) (all used by less than 10%
of the laboratories).
There were no differences in error rates and overall performance characteristics between
GeneXpert and other NAAT methods for rapid MTB complex bacteria identification.
Module 6 –Molecular DST on cultures
In Module 6, proficiency of laboratories in rapidly detecting resistance to selected first (INH,
RIF, and EMB) and second-line drugs (FQ like Oxofloxacin or Moxifloxacin, and the injectables
AMK, KAN, and CAP) on cultures was tested. The number of participants remained relatively
stable over five years and ranged from 18 (Round 1) to 22 (Round 2). Nearly all laboratories
used line probe assays (LPAs) for molecular DST. A small number of laboratories (<10%) used
in-house validated assays including targeted gene sequencing and pyrosequencing,
Performance was good with only one laboratory in round 6 failing to achieve the 80%
threshold score. The proportion of laboratories adopting technologies for rapid DST for sec-
ond-line drugs increased from 66.7% (round 2) to 85.0% (round 6). Overall concordance with
reference results was high, exceeding 99% for all drugs (Fig 4). Unlike the phenotypic tests,
there was no significant variation and error rates were generally very low (<1.0%) for both first
and second-line drugs (Fig 4) demonstrating excellent proficiency of participating laboratories
in rapid DST and overall feasibility of molecular tests.
Module 7 –Molecular DST on crude extracts
The primary aim of this module was to test the proficiency of the laboratories in rapid detec-
tion of highly drug-resistantM. tuberculosis strains, and therefore inactivated non-hazardous
crude DNA extracts isolated from fully sensitive, poly- and multidrug-resistant strains were
used. Module 7 panels were only included in rounds 3 and 4 and results were obtained from 26
and 24 laboratories, respectively.
Overall performance was good with a total of 8 errors reported (comprising 0.6% of all tests
performed within the module). All laboratories achieved scores>80%. Errors were not con-
fined to any specific drug and were lower for RIF (0.3%) and higher for INH (1.0%) (Fig 4).
Concordance with the reference values was>99% for all drugs and groups of drugs. Since per-
formance of all participating laboratories in Module 7 in two consecutive years was excellent, it
was decided to discontinue Module 7 to minimise associated shipping and laboratory costs.
Discussion
The primary aim of this study was to systematically analyse the performance of national TB
reference laboratories for detection, identification and drug susceptibility testing for TB diag-
nosis across the EU/EEA through a comprehensive series of EQA rounds, identify common
problems and discuss the potential benefits of the EQA scheme developed within the EU-wide
TB reference laboratory network.
Overall, laboratories demonstrated good proficiency with scores consistently exceeding the
80% threshold in the vast majority of the laboratories. Steady high performance in both pheno-
typic and rapid molecular methods over five years with only 27 individual module result fail-
ures (3.4% of the total) shows an ability of national TB Reference laboratories to diagnose TB
and drug resistance TB with high accuracy in a timely manner. The principal results of our
study were in agreement with another report [15] demonstrating the sustainability in TB diag-
nostic laboratories’ performance achieved over the last decade through activities of several col-
laborative projects including Nordic-Baltic TB Network, FP7 TB PANNET and other
initiatives [18,19].
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Challenges with microscopy and species identification in rounds 1–3 have been addressed
through corrective actions including additional training and laboratory visits. No major prob-
lems were detected in primary isolation (module 2). An in-depth analysis of laboratory perfor-
mance for phenotypic DST has allowed us to identify methodological problems with specific
anti-TB drugs including PZA, EMB and, interestingly, KAN and AMK. This is largely in agree-
ment with earlier reports demonstrating a lack of standardised methodologies and drug con-
centrations for PZA (type of media) and KAN (use of mono- or disulphate salts) [15,19,20]
and highlights the importance of developing novel and/or improving existing methods for phe-
notypic DST for certain drugs It also shows the advantages of molecular tools as their labora-
tory performance did not depend on the drug tested in our study and agreement rates with
reference results were generally better compared to phenotypic tests. Overall performance of
phenotypic DST for key drugs (RIF, INH, FQ) was good and demonstrated the capacity of
most participating laboratories to reliably detect MDR and XDR TB. Noteworthy, the quality
of TB detection in our study did not depend on the method used. This suggests that reproduc-
ibility and performance characteristics of established and novel methods in microscopy and
identification of mycobacteria do not vary greatly, providing adequate quality control measures
are in place.
Proficiency of laboratories in identification and DST using rapid molecular tools proved to
be good and excellent. High scores were achieved by the laboratories in molecular DST on cul-
tures and crude extracts and there was a significant increase in the number of laboratories
adopting molecular techniques (particularly the GeneXpert system), which is critical for the
timely detection of MDR strains and prevention of transmission [4,5].
Our study identified several common challenges in EQA schemes with relatively low partici-
pation rates being one of them. Significant variability of participation rates (52.9–94.1%) across
modules and/or EQA rounds can be in part explained by the fact that not all laboratories per-
form all the tests routinely (e.g. microscopy, primary isolation or second line DST); data col-
lected outside the current study suggests that up to 25% of NRLs are not routinely engaged in
primary laboratory work (unpublished data). A small number of laboratories encountered
challenges in sending the results within the agreed timeframe or were unable to take part due
to financial constraints (although the EQA itself was free for all participating laboratories).
This highlights the importance of adequate management and careful financial planning includ-
ing allocation of funds for participation in EQA schemes. Other problems encountered in indi-
vidual laboratories preventing them achieving the 80% threshold included clerical errors
(mislabelling etc), incorrect interpretation of molecular and phenotypic tests results, as well as
cross-contamination issues. These problems may be indicative of more general problems in the
laboratory practice and should be taken into account in the laboratory quality management.
Conclusions
Laboratory services play a crucial role in improving the delivery of health care and reducing
the prevalence of TB and drug-resistant TB in particular. Quality assessment through profi-
ciency testing is a fundamental tool used to ensure accuracy of test results by comparing quality
between laboratories, evaluating performance and detecting errors so that corrective actions,
including additional training and support visits, can be taken in a timely manner to restore the
high quality of services.
Overall, results of our study and earlier reports on proficiency testing and EQA schemes for
M.tuberculosis genotyping [13,14] demonstrated that networking activities such as through the
ERLTB-Net can develop and implement a sustainable EQA system and maintain high quality
TB laboratory diagnosis. Regular free EQA rounds have proven essential in establishing the
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current performance and identifying strengths and challenges in laboratory diagnosis of TB in
the EU/EEA. The EQA scheme developed within ERLTB-Net project could be expanded to
national TB laboratory networks since the EQA constitutes an essential component of the sup-
port activities provided by NRLs to regional laboratories.
Participating laboratories benefited from the developed EQA program in a number of ways
including free of charge EQA and performance certificates essential for their accreditation by
relevant national bodies, availability of training for their staff members as well as targeted
actions including direct consultations with the EQA providers and support visits from scien-
tists within the network who were able to provide additional expertise and help to NRLs where
needed. Steadily high performance during the implementation period suggests that aforemen-
tioned network activities addressing the challenges identified through the analysis of EQA
results were effective. Sustainability of EQA and training activities at EU/EEA level as well as
their further development through inclusion of novel validated methodologies (eg Next Gener-
ation Sequencing) are crucial for ensuring timely and high-quality laboratory diagnosis of TB
in the EU/EEA.
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